David J. Bearss

Company: Halia Therapeutics, Inc

Job title: CSO & President

Seminars:

First-in-Class Allosteric Inhibitor of NEK7 to Block NLRP3 Inflammasome Assembly 12:00 pm

Allosteric inhibition of NEK7 stops NLRP3 complexing NLRP3 complexing can be reversed through NEK7 inhibition Further, NEK7 inhibition initiates downstream changes in inflammatory signalling & suppresses pro-inflammatory cytokine propagationRead more

day: Day 1 - Track B - Morning